Analysis suggests intermediate glucose control may suit patients with sepsis and cardiac disease, while those with neurological illness could benefit from stricter targets.
A new study in Nursing in Critical Care suggests that the best blood glucose target for critically ill patients may depend on why they are in intensive care, adding to long-running debate over how tightly to control sugar levels in the sickest adults. Using both a retrospective cohort from the MIMIC-IV database and a network meta-analysis of randomised trials, the authors reported that intermediate strict control appeared most favourable in sepsis and cardiac disease, while stricter control looked better in neurological illness.
The paper combined two approaches to address a question that has produced mixed results for years: whether tighter glucose control improves survival or instead raises the risk of dangerous hypoglycaemia, a condition in which blood sugar falls too low. In the retrospective analysis, the researchers examined time-weighted average glucose, which reflects blood sugar levels over time rather than a single reading. They reported that in patients with sepsis and cardiac disease, the lowest mortality risk was seen with a time-weighted average glucose of 110 to 150 mg/dL. In neurological patients, by contrast, the most favourable outcome was linked with stricter control in the 80 to 110 mg/dL range.
That finding sits between two established camps in the wider literature. A 2019 meta-analysis of 10 cohort studies involving 26,429 patients with sepsis found a U-shaped relationship between glucose and mortality, with the lowest death rates around 145 to 155 mg/dL in both diabetic and non-diabetic patients. The same analysis suggested that diabetic patients whose glucose fell below 145 mg/dL may fare worse than those without diagnosed diabetes, underlining the possibility that overly low targets can be harmful in sepsis.
Randomised trial evidence has also tended to caution against aggressive lowering. A 2016 systematic review and network meta-analysis of 36 trials involving 17,996 critically ill adults found no mortality advantage for tight glucose control over very mild control, but it did find a fivefold rise in severe hypoglycaemia. An updated meta-analysis published in 2018 similarly concluded that intensive glucose control did not significantly reduce mortality compared with conventional approaches, while increasing the risk of hypoglycaemia. Taken together, those findings have helped shift practice away from universal tight control and towards a more measured approach.
The new study’s main message is that one glucose target may not fit every critically ill patient. Its combined observational and trial-based analysis points towards tailoring glucose management to the underlying condition rather than using a single threshold across the intensive care unit. That is especially relevant in sepsis, where both too little and too much glucose appear risky, and in neurological disease, where the balance may differ enough to justify stricter control.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
